1
|
Niimi N, Yako H, Tsukamoto M, Takaku S, Yamauchi J, Kawakami E, Yanagisawa H, Watabe K, Utsunomiya K, Sango K. Involvement of oxidative stress and impaired lysosomal degradation in amiodarone-induced schwannopathy. Eur J Neurosci 2016; 44:1723-33. [PMID: 27152884 DOI: 10.1111/ejn.13268] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 04/28/2016] [Accepted: 04/28/2016] [Indexed: 12/14/2022]
Abstract
Amiodarone hydrochloride (AMD), an anti-arrhythmic agent, has been shown to cause peripheral neuropathy; however, its pathogenesis remains unknown. We examined the toxic effects of AMD on an immortalized adult rat Schwann cell line, IFRS1, and cocultures of IFRS1 cells and adult rat dorsal root ganglion neurons or nerve growth factor-primed PC12 cells. Treatment with AMD (1, 5, and 10 μm) induced time- and dose-dependent cell death, accumulation of phospholipids and neutral lipids, upregulation of the expression of gangliosides, and oxidative stress (increased nuclear factor E2-related factor in nuclear extracts and reduced GSH/GSSG ratios) in IFRS1 cells. It also induced the upregulation of LC3-II and p62 expression, with phosphorylation of p62, suggesting that deficient autolysosomal degradation is involved in AMD-induced IFRS1 cell death. Furthermore, treatment of the cocultures with AMD induced detachment of IFRS1 cells from neurite networks in a time- and dose-dependent manner. These findings suggest that AMD-induced lysosomal storage accompanied by enhanced oxidative stress and impaired lysosomal degradation in Schwann cells might be a cause of demyelination in the peripheral nervous system.
Collapse
Affiliation(s)
- Naoko Niimi
- Diabetic Neuropathy Project (Former ALS/Neuropathy Project), Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, 156-8506, Japan
| | - Hideji Yako
- Diabetic Neuropathy Project (Former ALS/Neuropathy Project), Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, 156-8506, Japan
| | - Masami Tsukamoto
- Diabetic Neuropathy Project (Former ALS/Neuropathy Project), Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, 156-8506, Japan.,Division of Diabetes, Metabolism & Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan
| | - Shizuka Takaku
- Diabetic Neuropathy Project (Former ALS/Neuropathy Project), Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, 156-8506, Japan
| | - Junji Yamauchi
- Department of Pharmacology, National Research Institute for Child Health and Development, Setagaya, Tokyo, Japan
| | - Emiko Kawakami
- Diabetic Neuropathy Project (Former ALS/Neuropathy Project), Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, 156-8506, Japan
| | - Hiroko Yanagisawa
- Diabetic Neuropathy Project (Former ALS/Neuropathy Project), Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, 156-8506, Japan
| | - Kazuhiko Watabe
- Diabetic Neuropathy Project (Former ALS/Neuropathy Project), Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, 156-8506, Japan
| | - Kazunori Utsunomiya
- Division of Diabetes, Metabolism & Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan
| | - Kazunori Sango
- Diabetic Neuropathy Project (Former ALS/Neuropathy Project), Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, 156-8506, Japan
| |
Collapse
|
3
|
Lu J, Miyakawa K, Roth RA, Ganey PE. Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress. Toxicol Sci 2012; 131:164-78. [PMID: 23042730 DOI: 10.1093/toxsci/kfs289] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Amiodarone (AMD), a class III antiarrhythmic drug, causes idiosyncratic hepatotoxicity in human patients. We demonstrated previously that tumor necrosis factor-alpha (TNF-α) plays an important role in a rat model of AMD-induced hepatotoxicity under inflammatory stress. In this study, we developed a model in vitro to study the roles of caspase activation and oxidative stress in TNF potentiation of AMD cytotoxicity. AMD caused cell death in Hepa1c1c7 cells, and TNF cotreatment potentiated its toxicity. Activation of caspases 9 and 3/7 was observed in AMD/TNF-cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity. Intracellular reactive oxygen species (ROS) generation and lipid peroxidation were observed after treatment with AMD and were further elevated by TNF cotreatment. Adding water-soluble antioxidants (trolox, N-acetylcysteine, glutathione, or ascorbate) produced only minor attenuation of AMD/TNF-induced cytotoxicity and did not influence the effect of AMD alone. On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/TNF cotreatment. α-TOCO plus a pancaspase inhibitor completely abolished AMD/TNF-induced cytotoxicity. In summary, activation of caspases and oxidative stress were observed after AMD/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.
Collapse
Affiliation(s)
- Jingtao Lu
- Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, USA
| | | | | | | |
Collapse
|
4
|
Haddad Y, Vallerand D, Brault A, Spénard J, Haddad PS. NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA. Int J Hepatol 2011; 2011:136816. [PMID: 22013536 PMCID: PMC3195504 DOI: 10.4061/2011/136816] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Accepted: 06/20/2011] [Indexed: 12/21/2022] Open
Abstract
We explored the therapeutic effect of NCX 1000, a derivative of ursodeoxycholic acid (UDCA) with nitric oxide (NO) donating properties, alone or in combination with vitamin E, in an experimental model of NASH in the rat. Methods. A control group was fed a standard liquid diet (Control), and the NASH groups were fed a high-fat liquid diet for 12 weeks without (NASH) or with simultaneous daily gavage with either NCX 1000 at 15 or 30 mg/kg (N15 and N30, resp.), or N15 plus vitamin E 100 mg/kg (N15 + VitE) for the last 6 weeks; UDCA 17.2 mg/kg was used as a reference. Results. NASH rats developed all key features of the disease. Treatments with N30 improved liver histology, decreased lipid peroxidation, and completely suppressed increases in LDH release, plasma insulin, and TNF-α. It also decreased O(2) (∙-) release and returned liver weight and glutathione back to normal. All effects were similar to the reference treatment, UDCA. The N15 treatment was less efficient than the N30 group, but became comparable to the latter when combined to vitamin E. Conclusion. Our study demonstrates that NCX 1000 has potent cytoprotective, antioxidant, and hypoinsulinemic properties that can be enhanced by combination with vitamin E.
Collapse
Affiliation(s)
- Yara Haddad
- Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology Université de Montréal and Montreal Diabetes Research Center, Montreal, QC, Canada H3C 3J7,Institute of Nutraceutical and Functional Foods, Laval University, Sillery, QC, Canada GIV 0A6
| | - Diane Vallerand
- Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology Université de Montréal and Montreal Diabetes Research Center, Montreal, QC, Canada H3C 3J7,Institute of Nutraceutical and Functional Foods, Laval University, Sillery, QC, Canada GIV 0A6
| | - Antoine Brault
- Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology Université de Montréal and Montreal Diabetes Research Center, Montreal, QC, Canada H3C 3J7,Institute of Nutraceutical and Functional Foods, Laval University, Sillery, QC, Canada GIV 0A6
| | - Jean Spénard
- Department of Pharmacology, Université de Montréal, Montreal, QC, Canada H3C 3J7,R & D Axcan Pharma Inc, Mont-St-Hilaire, QC, Canada J3H 6C4
| | - Pierre S. Haddad
- Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology Université de Montréal and Montreal Diabetes Research Center, Montreal, QC, Canada H3C 3J7,Institute of Nutraceutical and Functional Foods, Laval University, Sillery, QC, Canada GIV 0A6,*Pierre S. Haddad:
| |
Collapse
|
6
|
Robin MA, Descatoire V, Pessayre D, Berson A. Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory-Denk body formation. Toxicol In Vitro 2008; 22:1511-9. [DOI: 10.1016/j.tiv.2008.05.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2007] [Revised: 05/13/2008] [Accepted: 05/14/2008] [Indexed: 01/24/2023]
|